Page 192 - Read Online

Page 10 of 11 Costa et al. Hepatoma Res 2018;4:35 I http://dx.doi.org/10.20517/2394-5079.2018.06

B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS,
Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser
W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais
DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar
MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA,
Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N,
Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz
SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM,
McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad
AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, O’Donnell M, Omer SB, Ortblad K, Osborne R,
Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA 3rd, Porrini E, Pourmalek
F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De León FR, Rosenfeld LC, Rushton L, Sacco RL,
Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor
JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang
M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD,
Murray CJ, AlMazroa MA, Memish ZA. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a
systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-128.
5. Llovet J, Villanueva A, Lachenmayer A, Finn R. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev
Clin Oncol 2015;12:408-24.
6. Rtveladze K, Marsh T, Webber L, Kilpi F, Levy D, Conde W, McPherson K, Brown M. Health and economic burden of obesity in Brazil.
PLoS One 2013;8:e68785.
7. Wu J. Utilization of animal models to investigate non-alcoholic steatohepatitis-associated hepatocellular carcinoma. Oncotarget
2016;7:42762-76.
8. Asgharpour A, Cazanave SC, Pacana T, Seneshaw M, Vincent R, Banini BA, Kumar DP, Daita K, Min HK, Mirshahi F, Bedossa P, Sun
X, Hoshida Y, Koduru SV, Contaifer D Jr, Warncke UO, Wijesinghe DS, Sanyal AJ. A diet-induced animal model of non-alcoholic fatty
liver disease and hepatocellular cancer. J Hepatol 2016;65:579-88.
9. Tsatsoulis A, Mantzaris MD, Bellou S, Andrikoula M. Insulin resistance: an adaptive mechanism becomes maladaptive in the current
environment - an evolutionary perspective. Metabolism 2013;62:622-33.
10. Sanches SC, Ramalho LN, Augusto MJ, da Silva DM, Ramalho FS. Non-alcoholic steatohepatitis: a search for factual animal models.
Biomed Res Int 2015;2015:574832.
11. de Lima VM, Oliveira CP, Alves VA, Chammas MC, Oliveira EP, Stefano JT, de Mello ES, Cerri GG, Carrilho FJ, Caldwell SH. A rodent
model of NASH with cirrhosis, oval cell proliferation, and hepatocellular carcinoma. J Hepatol 2008;49:1055-61.
12. Groß C, Steiger K, Sayyed S, Heid I, Feuchtinger A, Walch A, Heß J, Unger K, Zitzelsberger H, Settles M, Schlitter AM, Dworniczak
J, Altomonte J, Ebert O, Schwaiger M, Rummeny E, Steingötter A, Esposito I, Braren R. Model matters: differences in orthotopic rat
hepatocellular carcinoma physiology determine therapy response to sorafenib. Clin Cancer Res 2015;21:4440-50.
13. Park JH, Kang JH, Lee YJ, Kim KI, Lee TS, Kim KM, Park JA, Ko YO, Yu DY, Nahm SS, Jeon TJ, Park YS, Lim SM. Evaluation of
diethylnitrosamine- or hepatitis B virus X gene-induced hepatocellular carcinoma with 18F-FDG PET/CT: a preclinical study. Oncol Rep
2015;33:347-53.
14. Carvalho CF, Chammas MC, Souza de Oliveira CP, Cogliati B, Carrilho FJ, Cerri GG. Elastography and contrast-enhanced
ultrasonography in the early detection of hepatocellular carcinoma in an experimental model of non-alcoholic steatohepatitis. J Clin Exp
Hepatol 2013;3:96-101.
15. Park SI, Lee JH, Ham HJ, Jung YJ, Park MS, Lee J, Maeng LS, Chung YA, Jang KS. Evaluation of 2-[18F]-fluoro-2-deoxy-D-glucose
positron emission tomography/computed tomography in rat models with hepatocellular carcinoma with liver cirrhosis. Biomed Mater Eng
2015;26 Suppl 1:S1669-76.
16. Cho E, Jun CH, Kim BS, Son DJ, Choi WS, Choi SK. 18F-FDG PET CT as a prognostic factor in hepatocellular carcinoma. Turk J
Gastroenterol 2015;26:344-50.
17. Kim YI, Paeng JC, Cheon GJ, Suh KS, Lee DS, Chung JK, Kang KW. Prediction of post-transplantation recurrence of hepatocellular
carcinoma using metabolic and volumetric indices of 18F-FDG PET/CT. J Nucl Med 2016;57:1045-51.
18. Sun DW, An L, Wei F, Mu L, Shi XJ, Wang CL, Zhao ZW, Li TF, Lv GY. Prognostic significance of parameters from pretreatment (18)
F-FDG PET in hepatocellular carcinoma: a meta-analysis. Abdom Radiol (NY) 2016;41:33-41.
19. Lee SD, Lee B, Kim SH, Joo J, Kim SK, Kim YK, Park SJ. Proposal of new expanded selection criteria using total tumor size and
(18)F-fluorodeoxyglucose - positron emission tomography/computed tomography for living donor liver transplantation in patients with
hepatocellular carcinoma: The National Cancer Center: Korea criteria. World J Transplant 2016;6:411-22.
20. Detry O, Govaerts L, Deroover A, Vandermeulen M, Meurisse N, Malenga S, Bletard N, Mbendi C, Lamproye A, Honoré P, Meunier
P, Delwaide J, Hustinx R. Prognostic value of (18)F-FDG PET/CT in liver transplantation for hepatocarcinoma. World J Gastroenterol
2015;21:3049-54.
21. Kornberg A, Küpper B, Tannapfel A, Büchler P, Krause B, Witt U, Gottschild D, Friess H. Patients with non-[18 F]fludeoxyglucose-avid
advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation. Liver
Transpl 2012;18:53-61.
22. Brito AF, Abrantes AM, Ribeiro M, Oliveira R, Casalta-Lopes J, Gonçalves AC, Sarmento-Ribeiro AB, Tralhão JG, Botelho MF.